Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: The involvement of cannabinoid CB1 receptors and apoptotic cell death

Toxicology and Applied Pharmacology

Volumn 274, Issue 1, 2014, Pages 17-23

  Tomiyama, Ken ichi ^a   Funada, Masahiko ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Apoptosis; Cannabinoid receptor; Cytotoxicity; Designer drug; Primary neuronal cells; Synthetic cannabinoid

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CASPASE 3; LIPOCORTIN 5; MICROTUBULE ASSOCIATED PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN CELL; BRAIN CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FOREBRAIN; IMMUNOFLUORESCENCE; MOUSE; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84889601799     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.10.028     Document Type: Article

References (23)

1. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 1995, 375:143-147.
2. 1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 1995, 270:13973-13980.
3. 1. Biochem. J. 1995, 312(Pt 2):637-641.
4. Derungs A., Schwaninger A.E., Mansella G., Bingisser R., Kraemer T., Liechti M.E. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013, 31:164-171.
5. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34:605-613.
6. Forney R.B. Toxicology of marihuana. Pharmacol. Rev. 1971, 23:279-284.
7. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1932-1936.
8. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., Thompson A.L., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 2005, 13:89-112.
9. Jerry J., Collins G., Streem D. Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon. Cleve. Clin. J. Med. 2012, 79:258-264.
10. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
11. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 1991, 40:471-478.
12. McQuade D., Hudson S., Dargan P.I., Wood D.M. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur. J. Clin. Pharmacol. 2013, 69:373-376.
13. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 1993, 44:1008-1015.
14. 1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000, 21:1735-1742.
15. Muller H., Sperling W., Kohrmann M., Huttner H.B., Kornhuber J., Maler J.M. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 2010, 118:309-310.
16. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
17. Nakajima J., Takahashi M., Nonaka R., Seto T., Suzuki J., Yoshida M., Kanai C., Hamano T. Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [S-35]GTP gamma S binding assays. Forensic Toxicol. 2011, 29:132-141.
18. Ohkuma S., Tomono S., Tanaka Y., Kuriyama K., Mukainaka T. Development of taurine biosynthesizing system in cerebral cortical neurons in primary culture. Int. J. Dev. Neurosci. 1986, 4:383-395.
19. Seely K.A., Lapoint J., Moran J.H., Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:234-243.
20. Tomiyama K., Funada M. Cytotoxicity of synthetic cannabinoids found in "Spice" products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol. Lett. 2011, 207:12-17.
21. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 2010, 198:31-38.
22. Uchiyama N., Kawamura M., Kikura-Hanajiri R., Goda Y. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci. Int. 2013, 227:21-32.
23. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch. Arztebl. Int. 2009, 106:464-467.